Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Section 3 of 6

Product information and disease description

231 evidence topics · 121 sources

Product description

Phase of product development

Launch

No evidence found.

Orphan drug, fast track, or breakthrough therapy designation for CIDP

No evidence found.

Product information

Generic, brand name and therapeutic class of product
Brand name

No evidence found.

Dosage forms and strengths
Average sales price and wholesale acquisition cost

Not applicable.

American hospital formulary service (AHFS), or other drug classification
AHFS class and ATC code assigned to claseprubart

No evidence found.

Indication
Pharmacology
Mechanism of action
Pharmacodynamics
In vitro affinity and potency compared with riliprubart
AssayDNTH103Riliprubart
Binding affinity to human active C1s, KD (KinExa)“9pM”“75pM”
Binding affinity to human active C1s, KD (SPR)“8pM”“35pM”
C4 cleavage by human active C1s, IC90 (nM)“0.47”“3.69”
Wieslab classical pathway assay in human serum, IC90 (μg/mL)“0.45”“5.4”
CH50 assay of RBC lysis in human serum, IC90 (μg/mL)“98”“668”
Liposome lysis in human serum, IC90 (μg/mL)“14.7”“39.8”
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on Claseprubart
Effects of Claseprubart on other drugs

No evidence found.

Dosing and administration
Dosage
Administration
Access and distribution
Co-prescribed/Concomitant therapies
Treatment at study entry: interim analysis of the first 40 participants
Prior treatment groupClaseprubart 300 mg every 2 weeks (N=40), n (%)
Standard of care treated“27 (67.5)”
Immunoglobulin“19 (47.5)”
Oral corticosteroids“8 (20.0)”
Standard of care refractory“9 (22.5)”
Treatment naive“4 (10.0)”
Effect of Claseprubart on quality measures

No evidence found.

Product comparison

Place of product in therapy

Disease description

Definition and etiology
Epidemiology
Incidence of Chronic inflammatory demyelinating polyneuropathy
Prevalence of Chronic inflammatory demyelinating polyneuropathy
Natural history, survival, and mortality
Mortality in the United States

No evidence found.

Pathophysiology
Systemic complement activation in serum and cerebrospinal fluid
Diagnosis
Clinical presentation - signs and symptoms
Long-term morbidity
Burden of Chronic inflammatory demyelinating polyneuropathy
Humanistic burden and health-related quality of life
Pain, fatigue, depression, and EQ-5D and SF-36 scores: systematic review of 7 humanistic burden studies

“Humanistic burden studies reported on the patient impact of CIDP on health-related quality of life (HRQoL), functioning, psychosocial welfare, productivity, pain, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“2009 assessed pain and fatigue, using the Numeric Pain Rating Scale (NPRS) and Fatigue Severity Scale (FSS) scores (n = 76), reporting that 17 and 74% of patients with CIDP reported severe pain and severe fatigue, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Two publications reported that 9 and 12.1% of patients had depression, based on hospital anxiety and depression scale (HADS) and the Beck Depression Inventory version II (BDI-II) scores in The Netherlands and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“EuroQol-5D (EQ-5D) scores among patients with CIDP were 0.62 and 0.68 for the UK and Germany, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A study of Dutch patients with CIDP (n = 76) also identified that patients scored below normative 36-Item Short Form Survey Instrument (SF-36) scores (50) for all the domains of the physical component and two of the domains of the mental component (vitality and social functioning)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic burden and healthcare resource utilization
Two-year all-cause costs and resource use versus matched controls in 790 newly diagnosed US adults
Hospitalizations, mobility aids, and productivity losses by disability level in 542 patients in five European countries

“Neurologists provided data on treatment, informal care, hospitalizations, mobility aids, and home modifications for 542 patients, while lost productivity was reported by a subset of patients ( n = 199).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Hospitalizations in the 12 months prior to the survey were more frequent with greater disability (mild 7.0%, moderate 14.5%, severe 21.6%; p < 0.001), as were emergency admissions (1.0, 9.9, 13.7% respectively; p < 0.001) and ICU stays (0.0, 0.7, 3.9% respectively; p = 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The use of mobility aids (19.1, 56.1, 89.7% respectively) and home modifications (12.8, 45.8, 74.2% respectively) also rose significantly with severity ( p < 0.001 for both).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Finally, work productivity losses among employed patients and activity impairment rose as disability increased (average percentage of productivity loss: mild 21.8%, moderate 44.0%, severe: 67.3%, p < 0.001; average daily activity impairment: mild 28.6%, moderate: 44.6%, severe: 68.1%, p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“As shown in Figure 4A , the proportion of patients employed at the time of the survey decreased with increasing disability severity (mild: 71.4%; moderate: 69.8%; severe: 39.1%; p = 0.049).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Economic impact of Chronic inflammatory demyelinating polyneuropathy on families
Economic impact of diagnostic testing

Approaches to treatment

Current treatment options and standard of care
Corticosteroids
Intravenous immunoglobulin
FDA-approved intravenous immunoglobulin products for CIDP: indications and dosing
Subcutaneous immunoglobulin
Plasma exchange
Immunosuppressants and rituximab
Neonatal fc receptor blockers
Subcutaneous efgartigimod randomized withdrawal trial: registry results for stage B time-to-event and disability outcomes
Stage B outcomeEfgartigimod PH20 SCPlacebo PH20 SC
Median time to first adjusted INCAT deterioration, days (95% CI)“NA[1] (NA to NA)”“140.0[2] (75.0 to NA)”
Median time to CIDP disease progression, days (95% CI)“NA[1] (247.0 to NA)”“85 (50.0 to 253.0)”
Mean (SD) change in adjusted INCAT score from stage B baseline“0.1(1.08)”“0.9(1.98)”
Subcutaneous efgartigimod randomized withdrawal trial: registry all-cause mortality and serious adverse events
EventStage A efgartigimod PH20 SCStage B efgartigimod PH20 SCStage B placebo PH20 SC
All-cause mortality, affected/at risk (%)“2/322 (0.62%)”“0/111 (0.00%)”“1/110 (0.91%)”
Serious adverse events, affected/at risk (%)“21/322 (6.52%)”“6/111 (5.41%)”“6/110 (5.45%)”
Limitations of current therapies
Summary

Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment; Sanofi states that, in people with CIDP who respond, about 70% of the response is considered incomplete. Approximately two-thirds of patients need long-term intravenous immunoglobulin, and in a US claims analysis 62% of immunoglobulin users were chronic users during the first year after the index date. Biomarkers of disease activity are lacking: in a withdrawal trial, 41% of participants withdrawn from intravenous immunoglobulin remained stable for 24 weeks, compared with 58% who continued it, and the lack of biomarkers can lead to potential overtreatment. After plasma exchange, 8 of 12 responders relapsed within 7 to 14 days of stopping. About 30% of survey respondents receiving intravenous immunoglobulin missed school or work because of infusions, and subcutaneous immunoglobulin typically requires administration once or twice a week. The Gamunex-C prescribing information carries a boxed warning for thrombosis, renal dysfunction, and acute renal failure, and states that renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous products in predisposed patients; observational studies indicate that corticosteroids carry a long-term risk of serious side effects.

Place in treatment, anticipated use, and care setting
Summary

In a US claims analysis of 3,409 individuals with CIDP, 2,758 (81%) were treated during the first year, and steroids (73% of those treated) followed by immunoglobulin (65%) were the most commonly used treatments. Neurology specialists are the most frequent prescribers of immunoglobulin, which may be given in a hospital clinic, physician's office, infusion clinic, or at home; the Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) prefilled syringe may be administered subcutaneously by patients or caregivers after proper instruction, and the vial is to be administered by a healthcare professional only.

The company positions claseprubart as a potential first-line biologic given as a subcutaneous, infrequently dosed, self-administered injection, and CAPTIVATE enrolls standard-of-care-refractory, standard-of-care-treated, and standard-of-care-naive patients without requiring immunoglobulin withdrawal. Other complement inhibitors are in development: Sanofi announced that the phase 3 MOBILIZE trial of riliprubart, an antibody that selectively inhibits activated C1s, in CIDP refractory to standard-of-care treatment will be stopped after an independent data monitoring committee determined at an interim analysis that it is unlikely to provide sufficient efficacy, and that continuation of VITALIZE will be evaluated accordingly; argenx is advancing two phase 3 trials of empasiprubart, an antibody targeting C2, one of them a head-to-head comparison with intravenous immunoglobulin.

Company positioning of claseprubart in CIDP
Heterogeneity of treatment effect
Care management intervention strategies
Immunoglobulin dose optimization and cessation trials
Home and subcutaneous administration
Outcome monitoring with disability, strength, and patient-reported scales
Other product development or post-marketing obligations required by the FDA

Not applicable.

Ongoing post-approval monitoring

Not applicable.

Expected outcomes of therapy